结合患者情况,调整为R-THOP+塞利尼索+泽布替尼方案,疗效显著,患者CNS病灶持续缩小。患者塞利尼索、泽布替尼维持至今,目前停化疗后1年,外周及中枢均完全缓解中,提示塞利尼索治疗中枢进展DLBCL效果显著,持续缓解且安全性良好。 参考文献: 1...
临床中,中枢神经系统(CNS)复发是弥漫大B细胞淋巴瘤(DLBCL)最严重的并发症之一,中位生存不到1年。塞利尼索作为全球首个全新机制的口服选择性核输出蛋白抑制剂,临床研究显示,其可透过血脑屏障对中枢神经系统淋巴瘤具有抗肿瘤活性1,与靶向...
On the other hand, recent studies have found no difference in CNS relapse rates between intercalated and EOT therapy but did identify a higher rate of treatment delays when therapy was given in an intercalated fashion. In a large, retrospective analysis of 1384 patients with DLBCL who received C...
Front-Line Treatment of DLBCL EP: 3.Relapsed and Refractory Diffuse Large B-Cell Lymphoma EP: 4.Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma EP: 5.CAR-T Therapy EP: 6.CAR-T Therapies in R/R DLBCL EP: 7.Safety With CAR-T Therapies in R/R DLBCL EP: 8.Real-...
A discussion of standard frontline treatment approaches and considerations for utilizing maintenance therapy for patients with germinal center B-cell and activated B-cell subtypes of diffuse large B-cell lymphoma.This is a modal window. The Playback API request failed for an unknown reason Error ...
CNS involvement was diagnosed as solely parenchymal in 41%, solely leptomeningeal in 43%, and paranchymal with leptomeningeal in 11% of the patients. Induction regimens were anthracycline‐based combined with high‐dose methotrexate (HD‐MTX) in 80% (n = 35) of patients, anthracycline‐based ...
Conclusions: Patients with stage I DLBCL and EN disease have a worse outcome than those with nodal involvement. Late relapses are common, including CNS relapses, requiring prolonged surveillance. Patients with EN stage I DLBCL may benefit from RT consolidation and is deserving of further study. ...
Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial. Read More The Road to Improving Diffuse Large B-Cell Lymphoma Treatment ...
The goal was to assess whether a dose-dense immunochemotherapy with early systemic CNS prophylaxis improves the outcome and reduces the incidence of CNS events. Treatment consisted of 2 courses of high-dose methotrexate in combination with biweekly rituximab (R), cyclophosphamide, doxorubicin, ...
3. Bobillo S, et al. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. Haematologica. 2018 Feb;103(2):e92-e93. 编辑:Cho...